Free shipping on all orders over $ 500

Pembrolizumab

Cat. No. M6102
Pembrolizumab Structure
Synonym:

Lambrolizumab; MK-3475

Size Price Availability Quantity
10mg USD 1050 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

In addition to Melanoma and Lung carcinoma, pembrolizumab has also demonstrated efficacy in other advanced solid tumors and hematologic malignancies. Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight
Formula
CAS Number 1374853-91-4
Purity >98%
Solubility
Storage at -20°C
References

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M, et al. N Engl J Med. 2016 Nov 10;375(19):1823-1833. PMID: 27718847.

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E, et al. Expert Rev Anticancer Ther. 2015;15(9):981-93. PMID: 26313415.

Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS, et al. Ann Pharmacother. 2015 Aug;49(8):907-37. PMID: 25991832.

Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, et al. N Engl J Med. 2015 May 21;372(21):2018-28. PMID: 25891174.

Related PD-1/PD-L1 Products
PD1-PDL1 inhibitor 1

PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction with IC50 value of 6 nM.

Atezolizumab

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

Nivolumab

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

BMS202

BMS202 (PD-1/PD-L1 inhibitor 2) is a inhibitor of the PD-1 (Programmed death- 1) /PD-L1 (Programmed death-ligand 1) protein/protein interaction with IC50 value of 18 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Pembrolizumab, Lambrolizumab; MK-3475 supplier, PD-1/PD-L1, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.